Fig. 8
From: Deciphering MOSPD1’s impact on breast cancer progression and therapeutic response
Impact of MOSPD1 on the drug sensitivity of Anti-PD-L1 in MCF-7 cell-derived xenografts in BC. Note (A) Comparative photographs of xenografts from sh-NC, sh-MOSPD1, and sh-MOSPD1 + Anti-PD-L1 groups of BC MCF-7 cells (n = 6). (B) Comparative analysis of the effect on the volume of MCF-7 cell-derived xenografts in sh-NC, sh-MOSPD1, and sh-MOSPD1 + Anti-PD-L1 groups (n = 6). (C) Comparative analysis of the effect on the weight of MCF-7 cell-derived xenografts in sh-NC, sh-MOSPD1, and sh-MOSPD1 + Anti-PD-L1 groups (n = 6). (D-E) Immunohistochemistry validation and quantitative analysis of changes in Ki-67 in MCF-7 cell-derived xenografts with MOSPD1 inhibition and Anti-PD-L1 intervention (n = 6). (F-G) Immunofluorescence validation and quantitative analysis of inhibiting MOSPD1 and Anti-PD-L1 effects on TUNEL in MCF-7 cell-derived xenografts (n = 6). (H) Flow cytometry detection and quantitative analysis of the effect of MOSPD1 silencing on Th2 cell numbers in tumor tissues of BC cell-derived xenografts (n = 6). (I) Impact of silencing MOSPD1 on the relative mRNA expression levels of IL-4, IL-5, and IL-13 in Th2 cells of BC cell-derived xenograft tumor tissues (n = 6). ** indicates P < 0.01